The FDA has just approved two new oral medications for gonorrhea, a common sexually transmitted infection. These medications are called Nuzolvence (zoliflodacin) and Blujepa (gepotidacin).
Nuzolvence comes as granules that dissolve in water. It can help adults and kids over 12 who weigh at least 77 pounds. Blujepa, on the other hand, is an oral tablet for patients over 12 who weigh at least 99 pounds. It’s especially for those who have limited treatment options.
Dr. Adam Sherwat, a director at the FDA, called these approvals a big step forward for treating uncomplicated urogenital gonorrhea. This type of gonorrhea is a localized infection that can cause painful urination and discharge. If not treated, it can lead to more severe issues, including infertility.
Historically, the standard treatment involved a shot of ceftriaxone plus an azithromycin pill. But recent guidelines now recommend just a single ceftriaxone shot. This change highlights the growing problem of drug resistance. As Dr. Peter Kim pointed out, we need more treatment options because gonorrhea is becoming resistant to traditional therapies.
In clinical trials, Nuzolvence was tested on 930 patients, where about 91% were cured after just one dose. In another study with Blujepa involving 628 patients, 93% experienced similar success. This shows both medications are as effective as the older treatments.
However, there are some side effects to be aware of. For Nuzolvence, they included low white blood cell counts, headaches, and nausea. Blujepa can cause stomach pain, dizziness, and could affect heart rhythm in some patients. It’s crucial for patients to discuss their health history with doctors before starting these treatments.
Both drugs were given Fast Track and Priority Review statuses by the FDA, speeding up their availability. Nuzolvence was developed by Entasis Therapeutics, while Blujepa is produced by GSK.
The rise in gonorrhea cases is a growing concern. According to the CDC, there were over 600,000 reported cases in the U.S. in 2021, marking a nearly 20% increase from the previous year. This underscores the importance of new treatment options and ongoing research.
As these new drugs become available, they bring hope for better management of gonorrhea and work to combat the rising issue of drug resistance.
Source link
